ConductScience.org, home

Paper2493053

Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.

Stötter H and 6 others. J Immunol, 1989. Cited by 83 papers, by iCite.

Cite this record

ConductScience Library. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. Papers, record 2493053. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2493053

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
PubMed
Journal
J Immunol
PubMed
Year
1989
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
83
iCite
Relative citation ratio, by iCite
2.13
iCite
Revised in PubMed
2011-11-17
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stötter HH
2Wiebke EAE A
3Tomita SS
4Belldegrun AA
5Topalian SS
6Rosenberg SAS A
7Lotze MTM T

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell MovementMajor topic
Cytotoxicity, ImmunologicMajor topic
Interferon Type IMajor topic
Interferon-gammaMajor topic
T-Lymphocytes, CytotoxicMajor topic
Tumor Cells, CulturedMajor topic
Antigens, Neoplasm
Antigens, Surface
Cell Adhesion Molecules
Cell Line
Dose-Response Relationship, Immunologic
HLA Antigens
Humans
Kinetics
Melanoma
Recombinant Proteins

Source PubMed

Download CSV of topics

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.

PMIDTitleJournalYearIn PapersSource
36341370Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?Front Immunol2022https://conductscience.org/library/papers/36341370PubMed
10849555
Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
Gene Ther2000https://conductscience.org/library/papers/10849555PubMed
10712667An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.Immunology2000https://conductscience.org/library/papers/10712667PubMed
9824505Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture.Immunology1998https://conductscience.org/library/papers/9824505PubMed
9353424Augmentation of impaired tumoricidal function in alveolar macrophages from lung cancer patients by cocultivation with allogeneic, but not autologous lymphocytes.Cancer Immunol Immunother1997https://conductscience.org/library/papers/9353424PubMed
8242663Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8242663PubMed
8101473Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8101473PubMed
8093857Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8093857PubMed
7917912Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.Br J Cancer1994https://conductscience.org/library/papers/7917912PubMed
7917907Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.Br J Cancer1994https://conductscience.org/library/papers/7917907PubMed
7913877Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.Cancer Immunol Immunother1994https://conductscience.org/library/papers/7913877PubMed
7902211Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.Cancer Immunol Immunother1993https://conductscience.org/library/papers/7902211PubMed
7541714Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.Cancer Res1995https://conductscience.org/library/papers/7541714PubMed
2407894Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.Klin Wochenschr1990https://conductscience.org/library/papers/2407894PubMed
2121676The in vivo anti-tumor effect of human recombinant interleukin-6.Jpn J Cancer Res1990https://conductscience.org/library/papers/2121676PubMed
1997108Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.Br J Cancer1991https://conductscience.org/library/papers/1997108PubMed
1968361Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.Cancer Immunol Immunother1990https://conductscience.org/library/papers/1968361PubMed
1968360Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid.Cancer Immunol Immunother1990https://conductscience.org/library/papers/1968360PubMed
1873855Human autologous tumor-specific T cells in malignant melanoma.Cancer Metastasis Rev1991https://conductscience.org/library/papers/1873855PubMed
1752779Human tumor-infiltrating lymphocytes transfected with tumor necrosis factor gene could augment cytotoxicity to autologous tumor cells.Jpn J Cancer Res1991https://conductscience.org/library/papers/1752779PubMed

See all 24 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALPK180216PubTator's text mininghttps://conductscience.org/library/genes/80216NCBI Gene
CD58965PubTator's text mininghttps://conductscience.org/library/genes/965NCBI Gene
ICAM13383PubTator's text mininghttps://conductscience.org/library/genes/3383NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2493053

GET https://conductscience.org/api/papers/v1/2493053/cited_by?page=2